NCT03771586View on ClinicalTrials.gov

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

December 17, 2018

Study Completion Date

January 2, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

SAGE-718

SAGE-718 in combination with Ketamine

DRUG

Placebo

Placebo in combination with Ketamine

Trial Locations (2)

90806

Sage Investigational Site, Long Beach

08009

Sage Investigational Site, Berlin

All Listed Sponsors
lead

Supernus Pharmaceuticals, Inc.

INDUSTRY

NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects | Biotech Hunter | Biotech Hunter